Atrium Therapeutics, Inc. Common Stock
Follow $RNA
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $RNA by emailVeridion Score
BETALOW CONF · 4 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is RNA moving today?
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
RNA overview
Related filings and maps
Congress activity in RNA
No receipt-qualified Congressional disclosure is present for RNA in the cached public ledger.
RNA contract awards, year to date.
Public federal awards linked to this ticker.
RNA lobbying filings, year to date.
Registered lobbying filings matched to Atrium Therapeutics, Inc. Common Stock.